{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:40:03Z","timestamp":1790703603442,"version":"4.1.0"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04906-9","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T03:39:23Z","timestamp":1779939563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antibody\u2013drug conjugates in colorectal cancer: molecular design, preclinical advances, and translational challenges"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2676-1153","authenticated-orcid":false,"given":"Md Arif","family":"Ansari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md","family":"Abubakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Mazharuddin","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabeeha","family":"Koya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janmejay","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Aazam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali Sandeep","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Murti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biplab","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachchida Nand","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palwinder","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-1855","authenticated-orcid":false,"given":"Smita","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4929-3954","authenticated-orcid":false,"given":"Nitesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"4906_CR1","doi-asserted-by":"publisher","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. Cancer J Clin 74(1). https:\/\/doi.org\/10.3322\/caac.21820","DOI":"10.3322\/caac.21820"},{"issue":"3","key":"4906_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"4906_CR3","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10389-023-01831-6","volume":"32","author":"Z Wu","year":"2024","unstructured":"Wu Z, Chen K, Li J, Dai X (2024) The global, regional, and national burden of colorectal cancer in 204 countries and territories from 1990 to 2019. J Public Health 32(4):609\u2013618. https:\/\/doi.org\/10.1007\/s10389-023-01831-6","journal-title":"J Public Health"},{"key":"4906_CR4","doi-asserted-by":"publisher","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics CA: a cancer journal for clinicians. 75(1):10. https:\/\/doi.org\/10.3322\/caac.21871","DOI":"10.3322\/caac.21871"},{"issue":"4","key":"4906_CR5","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2023","unstructured":"Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK et al (2023) Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis 10(4):1367\u20131401. https:\/\/doi.org\/10.1016\/j.gendis.2022.02.007","journal-title":"Genes Dis"},{"issue":"7","key":"4906_CR6","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1007\/s00120-021-01569-7","volume":"60","author":"IM Zraik","year":"2021","unstructured":"Zraik IM, Hess-Busch Y (2021) Management of chemotherapy side effects and their long-term sequelae. Der Urologe Ausg A 60(7):862\u2013871. https:\/\/doi.org\/10.1007\/s00120-021-01569-7","journal-title":"Der Urologe Ausg A"},{"key":"4906_CR7","doi-asserted-by":"publisher","unstructured":"Pysz I, Jackson PJ, Thurston DE (2019) Introduction to antibody\u2013drug conjugates (ADCs). In: Jackson DETPJM (ed) Drug Discovery Cytotoxic Payloads for Antibody \u2013 Drug Conjugates. The Royal Society of Chemistry. https:\/\/doi.org\/10.1039\/9781788012898-00001.","DOI":"10.1039\/9781788012898-00001"},{"key":"4906_CR8","doi-asserted-by":"publisher","unstructured":"Lewis JR (2023) Antibody-Drug Conjugates: Understanding Associated Drug Design and Pharmacology. AMWA Journal: Am Med Writers Association J 38(2). https:\/\/doi.org\/10.55752\/amwa.2023.224","DOI":"10.55752\/amwa.2023.224"},{"key":"4906_CR9","doi-asserted-by":"publisher","unstructured":"Sievers EL (2024) Principles of Antibody Drug Development. Precision Cancer Ther 2-Immunologic Approaches Treat Lymphoid Malignancies\u2010From Concept Pract 73\u201386. https:\/\/doi.org\/10.1002\/9781119824572.ch6","DOI":"10.1002\/9781119824572.ch6"},{"key":"4906_CR10","doi-asserted-by":"publisher","unstructured":"Brown JG, Loo D, Stahl K (2024) Preclinical Development of Antibody\u2013Drug Conjugates. A Comprehensive Guide to Toxicology in Nonclinical Drug Development. Elsevier, pp 671\u2013692. https:\/\/doi.org\/10.1016\/b978-0-323-85704-8.00024-4","DOI":"10.1016\/b978-0-323-85704-8.00024-4"},{"issue":"15","key":"4906_CR11","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.3390\/ijms21155510","volume":"21","author":"S Ponziani","year":"2020","unstructured":"Ponziani S, Di Vittorio G, Pitari G, Cimini AM, Ardini M, Gentile R et al (2020) Antibody-drug conjugates: the new frontier of chemotherapy. Int J Mol Sci 21(15):5510. https:\/\/doi.org\/10.3390\/ijms21155510","journal-title":"Int J Mol Sci"},{"issue":"10","key":"4906_CR12","doi-asserted-by":"publisher","first-page":"103311","DOI":"10.1016\/j.drudis.2022.06.011","volume":"27","author":"G Pander","year":"2022","unstructured":"Pander G, Uhl P, K\u00fchl N, Haberkorn U, Anderl J, Mier W (2022) Antibody\u2013drug conjugates: What drives their progress? Drug Discovery Today 27(10):103311. https:\/\/doi.org\/10.1016\/j.drudis.2022.06.011","journal-title":"Drug Discovery Today"},{"issue":"4","key":"4906_CR13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/bjc.2015.435","volume":"114","author":"N Diamantis","year":"2016","unstructured":"Diamantis N, Banerji U (2016) Antibody-drug conjugates\u2013an emerging class of cancer treatment. Br J Cancer 114(4):362\u2013367. https:\/\/doi.org\/10.1038\/bjc.2015.435","journal-title":"Br J Cancer"},{"issue":"4","key":"4906_CR14","doi-asserted-by":"publisher","first-page":"e00225","DOI":"10.1042\/BSR20150089","volume":"35","author":"C Peters","year":"2015","unstructured":"Peters C, Brown S (2015) Antibody\u2013drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep 35(4):e00225. https:\/\/doi.org\/10.1042\/BSR20150089","journal-title":"Biosci Rep"},{"issue":"1","key":"4906_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y (2022) Antibody drug conjugate: the biological missile for targeted cancer therapy. Signal Transduct Target Ther 7(1):93. https:\/\/doi.org\/10.1038\/s41392-022-00947-7","journal-title":"Signal Transduct Target Ther"},{"key":"4906_CR16","doi-asserted-by":"publisher","first-page":"1203073","DOI":"10.3389\/fimmu.2023.1203073","volume":"14","author":"D Aggarwal","year":"2023","unstructured":"Aggarwal D, Yang J, Salam MA, Sengupta S, Al-Amin MY, Mustafa S et al (2023) Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy. Front Immunol 14:1203073. https:\/\/doi.org\/10.3389\/fimmu.2023.1203073","journal-title":"Front Immunol"},{"issue":"3","key":"4906_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama K, Anami Y, Ha SY, Yamazaki CM (2024) Exploring the next generation of antibody\u2013drug conjugates. Nat Reviews Clin Oncol 21(3):203\u2013223. https:\/\/doi.org\/10.1038\/s41571-023-00850-2","journal-title":"Nat Reviews Clin Oncol"},{"issue":"1","key":"4906_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12935-022-02679-8","volume":"22","author":"HE Marei","year":"2022","unstructured":"Marei HE, Cenciarelli C, Hasan A (2022) Potential of antibody-drug conjugates (ADCs) for cancer therapy. Cancer Cell Int 22(1):255. https:\/\/doi.org\/10.1186\/s12935-022-02679-8","journal-title":"Cancer Cell Int"},{"issue":"3","key":"4906_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/antib10030030","volume":"10","author":"AT Lucas","year":"2021","unstructured":"Lucas AT, Moody A, Schorzman AN, Zamboni WC (2021) Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist\u2019s Perspective. Antibodies (Basel) 10(3):30. https:\/\/doi.org\/10.3390\/antib10030030","journal-title":"Antibodies (Basel)"},{"key":"4906_CR20","doi-asserted-by":"publisher","first-page":"1274088","DOI":"10.3389\/fphar.2023.1274088","volume":"14","author":"F Riccardi","year":"2023","unstructured":"Riccardi F, Dal Bo M, Macor P, Toffoli G (2023) A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy. Front Pharmacol 14:1274088. https:\/\/doi.org\/10.3389\/fphar.2023.1274088","journal-title":"Front Pharmacol"},{"issue":"5","key":"4906_CR21","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3390\/ph14050442","volume":"14","author":"V Kostova","year":"2021","unstructured":"Kostova V, Desos P, Starck JB, Kotschy A (2021) The Chemistry Behind ADCs. Pharmaceuticals (Basel) 14(5):442. https:\/\/doi.org\/10.3390\/ph14050442","journal-title":"Pharmaceuticals (Basel)"},{"issue":"10","key":"4906_CR22","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.3390\/molecules26102943","volume":"26","author":"S Baah","year":"2021","unstructured":"Baah S, Laws M, Rahman KM (2021) Antibody-Drug Conjugates-A Tutorial Review. Molecules 26(10):2943. https:\/\/doi.org\/10.3390\/molecules26102943","journal-title":"Molecules"},{"key":"4906_CR23","doi-asserted-by":"publisher","first-page":"1258700","DOI":"10.3389\/fimmu.2023.1258700","volume":"14","author":"K Schoenfeld","year":"2023","unstructured":"Schoenfeld K, Harwardt J, Habermann J, Elter A, Kolmar H (2023) Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting. Front Immunol 14:1258700. https:\/\/doi.org\/10.3389\/fimmu.2023.1258700","journal-title":"Front Immunol"},{"issue":"24","key":"4906_CR24","doi-asserted-by":"publisher","first-page":"7510","DOI":"10.1158\/0008-5472.CAN-14-2030","volume":"74","author":"B Vire","year":"2014","unstructured":"Vire B, Skarzynski M, Thomas JD, Nelson CG, David A, Aue G et al (2014) Harnessing the fc\u00b5 receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia. Cancer Res 74(24):7510\u20137520. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-2030","journal-title":"Cancer Res"},{"key":"4906_CR25","doi-asserted-by":"publisher","first-page":"113385","DOI":"10.1016\/j.ab.2019.113385","volume":"584","author":"ES Moh","year":"2019","unstructured":"Moh ES, Sayyadi N, Packer NH (2019) Chemoenzymatic glycan labelling as a platform for site-specific IgM-antibody drug conjugates. Anal Biochem 584:113385. https:\/\/doi.org\/10.1016\/j.ab.2019.113385","journal-title":"Anal Biochem"},{"key":"4906_CR26","doi-asserted-by":"publisher","first-page":"107917","DOI":"10.1016\/j.pharmthera.2021.107917","volume":"229","author":"Y Jin","year":"2022","unstructured":"Jin Y, Schladetsch MA, Huang X, Balunas MJ, Wiemer AJ (2022) Stepping forward in antibody-drug conjugate development. Pharmacol Ther 229:107917. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107917","journal-title":"Pharmacol Ther"},{"key":"4906_CR27","doi-asserted-by":"publisher","unstructured":"Chauhan J, McCraw AJ, Nakamura M, Osborn G, Sow HS, Cox VF et al (2020) IgE Antibodies against Cancer: Efficacy and Safety. Antibodies (Basel) 9(4). https:\/\/doi.org\/10.3390\/antib9040055","DOI":"10.3390\/antib9040055"},{"issue":"2","key":"4906_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/antib11020029","volume":"11","author":"S Crescioli","year":"2022","unstructured":"Crescioli S, White AL, Karagiannis SN (2022) Special Issue Antibody Engineering for Cancer Immunotherapy. Antibodies (Basel) 11(2):29. https:\/\/doi.org\/10.3390\/antib11020029","journal-title":"Antibodies (Basel)"},{"issue":"4","key":"4906_CR29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/14789450.2019.1578215","volume":"16","author":"A Beck","year":"2019","unstructured":"Beck A, D\u2019Atri V, Ehkirch A, Fekete S, Hernandez-Alba O, Gahoual R et al (2019) Cutting-edge multi-level analytical and structural characterization of antibody-drug conjugates: present and future. Expert Rev Proteom 16(4):337\u2013362. https:\/\/doi.org\/10.1080\/14789450.2019.1578215","journal-title":"Expert Rev Proteom"},{"issue":"16","key":"4906_CR30","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/c8cs00676h","volume":"48","author":"JD Bargh","year":"2019","unstructured":"Bargh JD, Isidro-Llobet A, Parker JS, Spring DR (2019) Cleavable linkers in antibody-drug conjugates. Chem Soc Rev 48(16):4361\u20134374. https:\/\/doi.org\/10.1039\/c8cs00676h","journal-title":"Chem Soc Rev"},{"issue":"1","key":"4906_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","volume":"9","author":"K Tsuchikama","year":"2018","unstructured":"Tsuchikama K, An Z (2018) Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell 9(1):33\u201346. https:\/\/doi.org\/10.1007\/s13238-016-0323-0","journal-title":"Protein Cell"},{"issue":"2","key":"4906_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1208\/s12248-014-9710-8","volume":"17","author":"JR McCombs","year":"2015","unstructured":"McCombs JR, Owen SC (2015) Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. AAPS J 17(2):339\u2013351. https:\/\/doi.org\/10.1208\/s12248-014-9710-8","journal-title":"AAPS J"},{"issue":"41","key":"4906_CR33","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.2174\/1381612826666200707131006","volume":"26","author":"P Shende","year":"2020","unstructured":"Shende P, Deshpande G (2020) Disulfide bond-responsive nanotherapeutic systems for the effective payload in cancer therapy. Curr Pharm Design 26(41):5353\u20135361. https:\/\/doi.org\/10.2174\/1381612826666200707131006","journal-title":"Curr Pharm Design"},{"key":"4906_CR34","doi-asserted-by":"publisher","DOI":"10.1039\/c8sc00256h","author":"B Stenton","year":"2018","unstructured":"Stenton B, Oliveira B, Matos M, Sinatra L, Bernardes G (2018) A thioether-directed palladium-cleavable linker for targeted bioorthogonal drug decaging. Chem. https:\/\/doi.org\/10.1039\/c8sc00256h","journal-title":"Chem"},{"issue":"8","key":"4906_CR35","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.1039\/d0cs01061h","volume":"50","author":"Y Xue","year":"2021","unstructured":"Xue Y, Bai H, Peng B, Fang B, Baell J, Li L et al (2021) Stimulus-cleavable chemistry in the field of controlled drug delivery. Chem Soc Rev 50(8):4872\u20134931. https:\/\/doi.org\/10.1039\/d0cs01061h","journal-title":"Chem Soc Rev"},{"issue":"1","key":"4906_CR36","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1039\/D3MD00473B","volume":"15","author":"L Wang","year":"2024","unstructured":"Wang L, Hobson AD, Fitzgibbons J, Hernandez A, Jia Y, Xu Z et al (2024) Impact of dipeptide on ADC physicochemical properties and efficacy identifies Ala\u2013Ala as the optimal dipeptide. RSC Med Chem 15(1):355\u2013365. https:\/\/doi.org\/10.1039\/D3MD00473B","journal-title":"RSC Med Chem"},{"issue":"40","key":"4906_CR37","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1016\/j.tetlet.2018.08.021","volume":"59","author":"D Mondal","year":"2018","unstructured":"Mondal D, Ford J, Pinney KG (2018) Improved Methodology for the Synthesis of a Cathepsin B Cleavable Dipeptide Linker, Widely Used in Antibody-Drug Conjugate Research. Tetrahedron Lett 59(40):3594\u20133599. https:\/\/doi.org\/10.1016\/j.tetlet.2018.08.021","journal-title":"Tetrahedron Lett"},{"issue":"11","key":"4906_CR38","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1039\/D1SC05243H","volume":"13","author":"N Zacharias","year":"2022","unstructured":"Zacharias N, Podust VN, Kajihara KK, Leipold D, Del Rosario G, Thayer D et al (2022) A homogeneous high-DAR antibody\u2013drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides. Chem Sci 13(11):3147\u20133160. https:\/\/doi.org\/10.1039\/D1SC05243H","journal-title":"Chem Sci"},{"key":"4906_CR39","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ejmech.2017.08.008","volume":"142","author":"S Kolodych","year":"2017","unstructured":"Kolodych S, Michel C, Delacroix S, Koniev O, Ehkirch A, Eberova J et al (2017) Development and evaluation of beta-galactosidase-sensitive antibody-drug conjugates. Eur J Med Chem 142:376\u2013382. https:\/\/doi.org\/10.1016\/j.ejmech.2017.08.008","journal-title":"Eur J Med Chem"},{"key":"4906_CR40","doi-asserted-by":"publisher","unstructured":"Wuersch K, Watson R Development of Antibody-Drug Conjugates (ADCs). In: Philip Bentley PSS, Zbigniew, Wojcinski (eds) Current Topics in Nonclinical Drug Development. Boca Raton: CRC. p. 372\u2013457https:\/\/doi.org\/10.1201\/9781003035800","DOI":"10.1201\/9781003035800"},{"issue":"32","key":"4906_CR41","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.2174\/1568026618666180118153502","volume":"17","author":"M Walles","year":"2017","unstructured":"Walles M, Connor A, Hainzl D (2017) ADME and safety aspects of non-cleavable linkers in drug discovery and development. Curr Top Med Chem 17(32):3463\u20133475. https:\/\/doi.org\/10.2174\/1568026618666180118153502","journal-title":"Curr Top Med Chem"},{"issue":"2","key":"4906_CR42","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jconrel.2003.12.009","volume":"95","author":"RG Schoenmakers","year":"2004","unstructured":"Schoenmakers RG, van de Wetering P, Elbert DL, Hubbell JA (2004) The effect of the linker on the hydrolysis rate of drug-linked ester bonds. J Controlled Release 95(2):291\u2013300. https:\/\/doi.org\/10.1016\/j.jconrel.2003.12.009","journal-title":"J Controlled Release"},{"issue":"9","key":"4906_CR43","doi-asserted-by":"publisher","first-page":"4979","DOI":"10.1021\/acs.analchem.6b00976","volume":"88","author":"C Wei","year":"2016","unstructured":"Wei C, Zhang G, Clark T, Barletta F, Tumey LN, Rago B et al (2016) Where did the linker-payload go? A quantitative investigation on the destination of the released linker-payload from an antibody-drug conjugate with a maleimide linker in plasma. Anal Chem 88(9):4979\u20134986. https:\/\/doi.org\/10.1021\/acs.analchem.6b00976","journal-title":"Anal Chem"},{"issue":"11","key":"4906_CR44","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","volume":"32","author":"N Jain","year":"2015","unstructured":"Jain N, Smith SW, Ghone S, Tomczuk B (2015) Current ADC Linker Chemistry. Pharm Res 32(11):3526\u20133540. https:\/\/doi.org\/10.1007\/s11095-015-1657-7","journal-title":"Pharm Res"},{"issue":"41","key":"4906_CR45","doi-asserted-by":"publisher","first-page":"13613","DOI":"10.1039\/D1SC02973H","volume":"12","author":"MS Kang","year":"2021","unstructured":"Kang MS, Kong TWS, Khoo JYX, Loh T-P (2021) Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody\u2013drug conjugates. Chem Sci 12(41):13613\u201313647. https:\/\/doi.org\/10.1039\/D1SC02973H","journal-title":"Chem Sci"},{"issue":"10","key":"4906_CR46","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1021\/jm2002958","volume":"54","author":"RY Zhao","year":"2011","unstructured":"Zhao RY, Wilhelm SD, Audette C, Jones G, Leece BA, Lazar AC et al (2011) Synthesis and evaluation of hydrophilic linkers for antibody\u2013maytansinoid conjugates. J Med Chem 54(10):3606\u20133623. https:\/\/doi.org\/10.1021\/jm2002958","journal-title":"J Med Chem"},{"issue":"7","key":"4906_CR47","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/leu.2009.77","volume":"23","author":"A Takeshita","year":"2009","unstructured":"Takeshita A, Yamakage N, Shinjo K, Ono T, Hirano I, Nakamura S et al (2009) CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells. Leukemia 23(7):1329\u20131336. https:\/\/doi.org\/10.1038\/leu.2009.77","journal-title":"Leukemia"},{"issue":"2","key":"4906_CR48","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.molimm.2014.09.014","volume":"67","author":"B Shor","year":"2015","unstructured":"Shor B, Gerber H-P, Sapra P (2015) Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol 67(2):107\u2013116. https:\/\/doi.org\/10.1016\/j.molimm.2014.09.014","journal-title":"Mol Immunol"},{"issue":"5","key":"4906_CR49","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corvaia N (2017) Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov 16(5):315\u2013337. https:\/\/doi.org\/10.1038\/nrd.2016.268","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"4906_CR50","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/bcr3621","volume":"16","author":"M Barok","year":"2014","unstructured":"Barok M, Joensuu H, Isola J (2014) Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res 16(2):209. https:\/\/doi.org\/10.1186\/bcr3621","journal-title":"Breast Cancer Res"},{"issue":"1","key":"4906_CR51","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41698-022-00338-9","volume":"7","author":"N Coleman","year":"2023","unstructured":"Coleman N, Yap TA, Heymach JV, Meric-Bernstam F, Le X (2023) Antibody-drug conjugates in lung cancer: dawn of a new era? NPJ Precis Oncol 7(1):5. https:\/\/doi.org\/10.1038\/s41698-022-00338-9","journal-title":"NPJ Precis Oncol"},{"issue":"13","key":"4906_CR52","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.3390\/ijms25136969","volume":"25","author":"AA Chis","year":"2024","unstructured":"Chis AA, Dobrea CM, Arseniu AM, Frum A, Rus LL, Cormos G et al (2024) Antibody-Drug Conjugates-Evolution and Perspectives. Int J Mol Sci 25(13):6969. https:\/\/doi.org\/10.3390\/ijms25136969","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4906_CR53","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1002\/med.21568","volume":"39","author":"KE Arnst","year":"2019","unstructured":"Arnst KE, Banerjee S, Chen H, Deng S, Hwang DJ, Li W et al (2019) Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy. Med Res Rev 39(4):1398\u20131426. https:\/\/doi.org\/10.1002\/med.21568","journal-title":"Med Res Rev"},{"issue":"7","key":"4906_CR54","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3390\/ph14070674","volume":"14","author":"M Hammood","year":"2021","unstructured":"Hammood M, Craig AW, Leyton JV (2021) Impact of endocytosis mechanisms for the receptors targeted by the currently approved antibody-drug conjugates (ADCs)\u2014a necessity for future ADC research and development. Pharmaceuticals 14(7):674. https:\/\/doi.org\/10.3390\/ph14070674","journal-title":"Pharmaceuticals"},{"issue":"8","key":"4906_CR55","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrm2216","volume":"8","author":"S Mayor","year":"2007","unstructured":"Mayor S, Pagano RE (2007) Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol 8(8):603\u2013612. https:\/\/doi.org\/10.1038\/nrm2216","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4906_CR56","doi-asserted-by":"publisher","first-page":"1669592","DOI":"10.3389\/fcell.2025.1669592","volume":"13","author":"L Shui","year":"2025","unstructured":"Shui L, Wu D, Yang K, He R, YIN R (2025) Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs. Front Cell Dev Biology 13:1669592. https:\/\/doi.org\/10.3389\/fcell.2025.1669592","journal-title":"Front Cell Dev Biology"},{"issue":"7","key":"4906_CR57","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","volume":"24","author":"F Giugliano","year":"2022","unstructured":"Giugliano F, Corti C, Tarantino P, Michelini F, Curigliano G (2022) Bystander effect of antibody-drug conjugates: fact or fiction? Curr Oncol Rep 24(7):809\u2013817. https:\/\/doi.org\/10.1007\/s11912-022-01266-4","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"4906_CR58","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10238-025-01655-6","volume":"25","author":"Y Lv","year":"2025","unstructured":"Lv Y, Cui X, Li T, Liu C, Wang A, Wang T et al (2025) Mechanism of action and future perspectives of ADCs in combination with immune checkpoint inhibitors for solid tumors. Clin Exp Med 25(1):139. https:\/\/doi.org\/10.1007\/s10238-025-01655-6","journal-title":"Clin Exp Med"},{"key":"4906_CR59","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.pharmthera.2017.07.013","volume":"181","author":"PA Trail","year":"2018","unstructured":"Trail PA, Dubowchik GM, Lowinger TB (2018) Antibody drug conjugates for treatment of breast cancer: novel targets and diverse approaches in ADC design. Pharmacol Ther 181:126\u2013142. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.07.013","journal-title":"Pharmacol Ther"},{"issue":"13","key":"4906_CR60","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.2174\/0929867327666200525161359","volume":"28","author":"R Petrilli","year":"2021","unstructured":"Petrilli R, Pinheiro DP, F de Oliveira deC\u00e1ssiaE, Galv\u00e3o GF, Marques LG, Lopez RFV et al (2021) Immunoconjugates for cancer targeting: a review of antibody-drug conjugates and antibody-functionalized nanoparticles. Curr Med Chem 28(13):2485\u20132520. https:\/\/doi.org\/10.2174\/0929867327666200525161359","journal-title":"Curr Med Chem"},{"issue":"2","key":"4906_CR61","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3390\/ijms24021702","volume":"24","author":"T Ohishi","year":"2023","unstructured":"Ohishi T, Kaneko MK, Yoshida Y, Takashima A, Kato Y, Kawada M (2023) Current Targeted Therapy for Metastatic Colorectal Cancer. Int J Mol Sci 24(2):1702. https:\/\/doi.org\/10.3390\/ijms24021702","journal-title":"Int J Mol Sci"},{"issue":"8","key":"4906_CR62","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s12094-010-0551-3","volume":"12","author":"J Garcia-Foncillas","year":"2010","unstructured":"Garcia-Foncillas J, Diaz-Rubio E (2010) Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clin Transl Oncol 12(8):533\u2013542. https:\/\/doi.org\/10.1007\/s12094-010-0551-3","journal-title":"Clin Transl Oncol"},{"issue":"14","key":"4906_CR63","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, K\u00f6hne C-H, Hitre E, Zaluski J, Chang Chien C-R, Makhson A et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14):1408\u20131417. https:\/\/doi.org\/10.1056\/NEJMoa0805019","journal-title":"N Engl J Med"},{"issue":"30","key":"4906_CR64","doi-asserted-by":"publisher","first-page":"26685","DOI":"10.1021\/acsomega.3c02424","volume":"8","author":"GM Hasan","year":"2023","unstructured":"Hasan GM, Hassan MI, Sohal SS, Shamsi A, Alam M (2023) Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma. ACS Omega 8(30):26685\u201326698. https:\/\/doi.org\/10.1021\/acsomega.3c02424","journal-title":"ACS Omega"},{"key":"4906_CR65","doi-asserted-by":"publisher","first-page":"S805","DOI":"10.1016\/j.annonc.2024.08.1314","volume":"35","author":"M De Miguel","year":"2024","unstructured":"De Miguel M, yamamoto N, Raimbourg J, Cho BC, Gottfried M, Stemmer SM et al (2024) 1257MO ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I study. Ann Oncol 35:S805\u2013S6. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.1314","journal-title":"Ann Oncol"},{"issue":"5","key":"4906_CR66","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3390\/cancers13051047","volume":"13","author":"K Yonesaka","year":"2021","unstructured":"Yonesaka K (2021) HER2-\/HER3-targeting antibody\u2014Drug conjugates for treating lung and colorectal cancers resistant to EGFR inhibitors. Cancers 13(5):1047. https:\/\/doi.org\/10.3390\/cancers13051047","journal-title":"Cancers"},{"issue":"1","key":"4906_CR67","doi-asserted-by":"publisher","first-page":"188827","DOI":"10.1016\/j.bbcan.2022.188827","volume":"1878","author":"JJ Kang","year":"2023","unstructured":"Kang JJ, Ko A, Kil SH, Mallen-St Clair J, Shin DS, Wang MB et al (2023) EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy. Biochim Biophys Acta Rev Cancer 1878(1):188827. https:\/\/doi.org\/10.1016\/j.bbcan.2022.188827","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"6","key":"4906_CR68","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s11864-023-01080-5","volume":"24","author":"P Tathineni","year":"2023","unstructured":"Tathineni P, Joshi N, Jelinek MJ (2023) Current state and future directions of EGFR-directed therapy in head and neck cancer. Curr Treat Options Oncol 24(6):680\u2013692. https:\/\/doi.org\/10.1007\/s11864-023-01080-5","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"4906_CR69","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3390\/vaccines10040499","volume":"10","author":"B Janani","year":"2022","unstructured":"Janani B, Vijayakumar M, Priya K, Kim JH, Prabakaran DS, Shahid M et al (2022) EGFR-Based Targeted Therapy for Colorectal Cancer-Promises and Challenges. Vaccines (Basel) 10(4):499. https:\/\/doi.org\/10.3390\/vaccines10040499","journal-title":"Vaccines (Basel)"},{"issue":"23","key":"4906_CR70","doi-asserted-by":"publisher","first-page":"12828","DOI":"10.3390\/ijms222312828","volume":"22","author":"WL Cheng","year":"2021","unstructured":"Cheng WL, Feng PH, Lee KY, Chen KY, Sun WL, Van Hiep N et al (2021) The Role of EREG\/EGFR Pathway in Tumor Progression. Int J Mol Sci 22(23):12828. https:\/\/doi.org\/10.3390\/ijms222312828","journal-title":"Int J Mol Sci"},{"key":"4906_CR71","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.semcdb.2014.03.005","volume":"28","author":"IIDJ Riese","year":"2014","unstructured":"Riese IIDJ, Cullum RL (2014) Epiregulin: roles in normal physiology and cancer. Semin Cell Dev Biol 28:49\u201356. https:\/\/doi.org\/10.1016\/j.semcdb.2014.03.005","journal-title":"Semin Cell Dev Biol"},{"key":"4906_CR72","doi-asserted-by":"publisher","first-page":"115039","DOI":"10.1016\/j.biopha.2023.115039","volume":"165","author":"S Zafar","year":"2023","unstructured":"Zafar S, Armaghan M, Khan K, Hassan N, Sharifi-Rad J, Habtemariam S et al (2023) New insights into the anticancer therapeutic potential of maytansine and its derivatives. Biomed Pharmacother 165:115039. https:\/\/doi.org\/10.1016\/j.biopha.2023.115039","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"4906_CR73","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1158\/1535-7163.MCT-10-0644","volume":"9","author":"M Lopus","year":"2010","unstructured":"Lopus M, Oroudjev E, Wilson L, Wilhelm S, Widdison W, Chari R et al (2010) Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther 9(10):2689\u20132699. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0644","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"4906_CR74","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/jphp.12911","volume":"70","author":"S Moradi-Kalbolandi","year":"2018","unstructured":"Moradi-Kalbolandi S, Hosseinzade A, Salehi M, Merikhian P, Farahmand L (2018) Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER. J Pharm Pharmacol 70(7):841\u2013854. https:\/\/doi.org\/10.1111\/jphp.12911","journal-title":"J Pharm Pharmacol"},{"issue":"10","key":"4906_CR75","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.18632\/oncotarget.26613","volume":"10","author":"SV Hartimath","year":"2019","unstructured":"Hartimath SV, El-Sayed A, Makhlouf A, Bernhard W, Gonzalez C, Hill W et al (2019) Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft. Oncotarget 10(10):1031\u20131044. https:\/\/doi.org\/10.18632\/oncotarget.26613","journal-title":"Oncotarget"},{"issue":"9","key":"4906_CR76","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.3390\/pharmaceutics14091917","volume":"14","author":"AF Tikum","year":"2022","unstructured":"Tikum AF, Nambisan AK, Ketchemen JP, Babeker H, Khan MN, Torlakovic EE et al (2022) Simultaneous imaging and therapy using epitope-specific anti-epidermal growth factor receptor (EGFR) antibody conjugates. Pharmaceutics 14(9):1917. https:\/\/doi.org\/10.3390\/pharmaceutics14091917","journal-title":"Pharmaceutics"},{"key":"4906_CR77","doi-asserted-by":"publisher","unstructured":"Benelli R, Costa D, Salvini L, Tardito S, Tosetti F, Villa F et al (2022) Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab. J Immunother Cancer 10(12). https:\/\/doi.org\/10.1136\/jitc-2022-005660","DOI":"10.1136\/jitc-2022-005660"},{"issue":"3","key":"4906_CR78","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3390\/cancers15030610","volume":"15","author":"JLC Fernandez","year":"2023","unstructured":"Fernandez JLC, Benelli R, Costa D, Campioli A, Tavella S, Zocchi MR et al (2023) Priming of Colorectal Tumor-Associated Fibroblasts with Zoledronic Acid Conjugated to the Anti-Epidermal Growth Factor Receptor Antibody Cetuximab Elicits Anti-Tumor Vdelta2 T Lymphocytes. Cancers (Basel) 15(3):610. https:\/\/doi.org\/10.3390\/cancers15030610","journal-title":"Cancers (Basel)"},{"issue":"7","key":"4906_CR79","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3390\/cancers16071256","volume":"16","author":"L Pisheh","year":"2024","unstructured":"Pisheh L, Matis S, Taglieri M, Di Gregorio L, Benelli R, Poggi A (2024) EGFR-Targeted Antibody\u2013Drug Conjugate to Different Aminobisphosphonates: Direct and Indirect Antitumor Effects on Colorectal Carcinoma Cells. Cancers 16(7):1256. https:\/\/doi.org\/10.3390\/cancers16071256","journal-title":"Cancers"},{"issue":"13","key":"4906_CR80","doi-asserted-by":"publisher","first-page":"7131","DOI":"10.3390\/ijms25137131","volume":"25","author":"S Tardito","year":"2024","unstructured":"Tardito S, Matis S, Zocchi MR, Benelli R, Poggi A (2024) Epidermal growth factor receptor targeting in colorectal carcinoma: antibodies and patient-derived organoids as a smart model to study therapy resistance. Int J Mol Sci 25(13):7131. https:\/\/doi.org\/10.3390\/ijms25137131","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4906_CR81","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1158\/0008-5472.CAN-24-0798","volume":"85","author":"J Jacob","year":"2025","unstructured":"Jacob J, Anami Y, High PC, Liang Z, Subramanian S, Ghosh SC et al (2025) Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer. Cancer Res 85(5):973\u2013986. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-0798","journal-title":"Cancer Res"},{"issue":"8","key":"4906_CR82","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.3390\/pharmaceutics15082020","volume":"15","author":"CM McKertish","year":"2023","unstructured":"McKertish CM, Kayser VA, Novel Dual-Payload (2023) ADC for the Treatment of HER2\u2009+\u2009Breast and Colon Cancer. Pharmaceutics 15(8):2020. https:\/\/doi.org\/10.3390\/pharmaceutics15082020","journal-title":"Pharmaceutics"},{"issue":"4","key":"4906_CR83","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1080\/15384047.2016.1139248","volume":"17","author":"H Li","year":"2016","unstructured":"Li H, Yu C, Jiang J, Huang C, Yao X, Xu Q et al (2016) An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer. Cancer Biol Ther 17(4):346\u2013354. https:\/\/doi.org\/10.1080\/15384047.2016.1139248","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"4906_CR84","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4161\/mabs.27022","volume":"6","author":"S Panowski","year":"2014","unstructured":"Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR (2014) Site-specific antibody drug conjugates for cancer therapy. MAbs 6(1):34\u201345. https:\/\/doi.org\/10.4161\/mabs.27022","journal-title":"MAbs"},{"issue":"3","key":"4906_CR85","doi-asserted-by":"publisher","first-page":"744","DOI":"10.3390\/cancers12030744","volume":"12","author":"Y Wang","year":"2020","unstructured":"Wang Y, Liu L, Fan S, Xiao D, Xie F, Li W et al (2020) Antibody-drug conjugate using ionized cys-linker-MMAE as the potent payload shows optimal therapeutic safety. Cancers 12(3):744. https:\/\/doi.org\/10.3390\/cancers12030744","journal-title":"Cancers"},{"issue":"1","key":"4906_CR86","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13046-023-02784-0","volume":"42","author":"JC Montero","year":"2023","unstructured":"Montero JC, Del Carmen S, Abad M, Sayagu\u00e9s JM, Barb\u00e1chano A, Fern\u00e1ndez-Barral A et al (2023) An amino acid transporter subunit as an antibody\u2013drug conjugate target in colorectal cancer. J Experimental Clin Cancer Res 42(1):200. https:\/\/doi.org\/10.1186\/s13046-023-02784-0","journal-title":"J Experimental Clin Cancer Res"},{"issue":"8","key":"4906_CR87","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3390\/cancers14082037","volume":"14","author":"A Cazes","year":"2022","unstructured":"Cazes A, Childers BG, Esparza E, Lowy AM (2022) The MST1R\/RON Tyrosine Kinase in Cancer: Oncogenic Functions and Therapeutic Strategies. Cancers (Basel) 14(8):2037. https:\/\/doi.org\/10.3390\/cancers14082037","journal-title":"Cancers (Basel)"},{"issue":"23","key":"4906_CR88","doi-asserted-by":"publisher","first-page":"6045","DOI":"10.1158\/1078-0432.CCR-14-0898","volume":"20","author":"L Feng","year":"2014","unstructured":"Feng L, Yao HP, Wang W, Zhou YQ, Zhou J, Zhang R et al (2014) Efficacy of anti-RON antibody Zt\/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy. Clin Cancer Res 20(23):6045\u20136058. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0898","journal-title":"Clin Cancer Res"},{"issue":"9","key":"4906_CR89","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/1878-0261.12520","volume":"13","author":"Y Tao","year":"2019","unstructured":"Tao Y, Wang R, Lai Q, Wu M, Wang Y, Jiang X et al (2019) Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinoma. Mol Oncol 13(9):1855\u20131873. https:\/\/doi.org\/10.1002\/1878-0261.12520","journal-title":"Mol Oncol"},{"key":"4906_CR90","doi-asserted-by":"publisher","unstructured":"Wu L, Zhao X, Ma H, Zhang L, Li X (2022) Discoidin Domain Receptor 1, a Potential Biomarker and Therapeutic Target in Hepatocellular Carcinoma. Int J Gen Med 2037\u20132044. https:\/\/doi.org\/10.2147\/IJGM.S348110","DOI":"10.2147\/IJGM.S348110"},{"issue":"4","key":"4906_CR91","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/19336918.2018.1465156","volume":"12","author":"E Henriet","year":"2018","unstructured":"Henriet E, Sala M, Abou Hammoud A, Tuariihionoa A, Di Martino J, Ros M et al (2018) Multitasking discoidin domain receptors are involved in several and specific hallmarks of cancer. Cell Adhes Migr 12(4):363\u2013377. https:\/\/doi.org\/10.1080\/19336918.2018.1465156","journal-title":"Cell Adhes Migr"},{"key":"4906_CR92","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fonc.2019.00167","volume":"9","author":"F Marcucci","year":"2019","unstructured":"Marcucci F, Caserta CA, Romeo E, Rumio C (2019) Antibody-drug conjugates (ADC) against cancer stem-like cells (CSC)\u2014Is there still room for optimism? Front Oncol 9:167. https:\/\/doi.org\/10.3389\/fonc.2019.00167","journal-title":"Front Oncol"},{"issue":"4","key":"4906_CR93","first-page":"610","volume":"8","author":"R Wang","year":"2018","unstructured":"Wang R, Lai Q, Tang L, Tao Y, Yao Y, Liu Y et al (2018) A novel 5T4-targeting antibody-drug conjugate H6-DM4 exhibits potent therapeutic efficacy in gastrointestinal tumor xenograft models. Am J cancer Res 8(4):610","journal-title":"Am J cancer Res"},{"issue":"23","key":"4906_CR94","doi-asserted-by":"publisher","first-page":"7151","DOI":"10.1158\/1078-0432.CCR-19-1745","volume":"25","author":"Y Hashimoto","year":"2019","unstructured":"Hashimoto Y, Koyama K, Kamai Y, Hirotani K, Ogitani Y, Zembutsu A et al (2019) A novel HER3-targeting antibody\u2013drug conjugate, U3-1402, exhibits potent therapeutic efficacy through the delivery of cytotoxic payload by efficient internalization. Clin Cancer Res 25(23):7151\u20137161. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1745","journal-title":"Clin Cancer Res"},{"issue":"11","key":"4906_CR95","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1158\/1535-7163.MCT-19-0452","volume":"18","author":"S Koganemaru","year":"2019","unstructured":"Koganemaru S, Kuboki Y, Koga Y, Kojima T, Yamauchi M, Maeda N et al (2019) U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer. Mol Cancer Ther 18(11):2043\u20132050. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-0452","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"4906_CR96","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/jcph.2137","volume":"63","author":"Y Lu","year":"2023","unstructured":"Lu Y, Shimizu S, Sawamura R, Tajima N, He L, Lee M et al (2023) Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors. J Clin Pharmacol 63(1):77\u201390. https:\/\/doi.org\/10.1002\/jcph.2137","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"4906_CR97","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s40262-017-0619-0","volume":"57","author":"WD Hedrich","year":"2018","unstructured":"Hedrich WD, Fandy TE, Ashour HM, Wang H, Hassan HE (2018) Antibody-Drug Conjugates: Pharmacokinetic\/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned. Clin Pharmacokinet 57(6):687\u2013703. https:\/\/doi.org\/10.1007\/s40262-017-0619-0","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"4906_CR98","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1021\/cb300648v","volume":"8","author":"Y Pommier","year":"2013","unstructured":"Pommier Y (2013) Drugging topoisomerases: lessons and challenges. ACS Chem Biol 8(1):82\u201395. https:\/\/doi.org\/10.1021\/cb300648v","journal-title":"ACS Chem Biol"},{"issue":"8","key":"4906_CR99","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41416-023-02192-3","volume":"128","author":"J Jacob","year":"2023","unstructured":"Jacob J, Francisco LE, Chatterjee T, Liang Z, Subramanian S, Liu QJ et al (2023) An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer. Br J Cancer 128(8):1592\u20131602. https:\/\/doi.org\/10.1038\/s41416-023-02192-3","journal-title":"Br J Cancer"},{"issue":"11","key":"4906_CR100","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1158\/1541-7786.MCR-19-0436","volume":"17","author":"S Zhang","year":"2019","unstructured":"Zhang S, Chatterjee T, Godoy C, Wu L, Liu QJ, Carmon KS (2019) GPR56 drives colorectal tumor growth and promotes drug resistance through upregulation of MDR1 expression via a RhoA-mediated mechanism. Mol Cancer Res 17(11):2196\u20132207. https:\/\/doi.org\/10.1158\/1541-7786.MCR-19-0436","journal-title":"Mol Cancer Res"},{"issue":"7","key":"4906_CR101","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3390\/pharmaceutics16070890","volume":"16","author":"P High","year":"2024","unstructured":"High P, Guernsey C, Subramanian S, Jacob J, Carmon KS (2024) The Evolving Paradigm of Antibody-Drug Conjugates Targeting the ErbB\/HER Family of Receptor Tyrosine Kinases. Pharmaceutics 16(7):890. https:\/\/doi.org\/10.3390\/pharmaceutics16070890","journal-title":"Pharmaceutics"},{"key":"4906_CR102","doi-asserted-by":"publisher","first-page":"100261","DOI":"10.1016\/j.jbc.2021.100261","volume":"296","author":"T Chatterjee","year":"2021","unstructured":"Chatterjee T, Zhang S, Posey TA, Jacob J, Wu L, Yu W et al (2021) Anti-GPR56 monoclonal antibody potentiates GPR56-mediated Src-Fak signaling to modulate cell adhesion. J Biol Chem 296:100261. https:\/\/doi.org\/10.1016\/j.jbc.2021.100261","journal-title":"J Biol Chem"},{"key":"4906_CR103","doi-asserted-by":"publisher","first-page":"216191","DOI":"10.1016\/j.canlet.2023.216191","volume":"564","author":"P High","year":"2023","unstructured":"High P, Carmon KS (2023) G protein-coupled receptor-targeting antibody-drug conjugates: Current status and future directions. Cancer Lett 564:216191. https:\/\/doi.org\/10.1016\/j.canlet.2023.216191","journal-title":"Cancer Lett"},{"issue":"5","key":"4906_CR104","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.bj.2021.04.012","volume":"44","author":"AK Singh","year":"2021","unstructured":"Singh AK, Lin H-H (2021) The role of GPR56\/ADGRG1 in health and disease. Biomedical J 44(5):534\u2013. https:\/\/doi.org\/10.1016\/j.bj.2021.04.012. \u200947","journal-title":"Biomedical J"},{"issue":"12","key":"4906_CR105","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1210\/mend.12.12.0211","volume":"12","author":"SY Hsu","year":"1998","unstructured":"Hsu SY, Liang SG, Hsueh AJ (1998) Characterization of two LGR genes homologous to gonadotropin and thyrotropin receptors with extracellular leucine-rich repeats and a G protein-coupled, seven-transmembrane region. Mol Endocrinol (Baltimore Md) 12(12):1830\u20131845. https:\/\/doi.org\/10.1210\/mend.12.12.0211","journal-title":"Mol Endocrinol (Baltimore Md)"},{"key":"4906_CR106","doi-asserted-by":"publisher","first-page":"1302488","DOI":"10.3389\/fimmu.2024.1302488","volume":"15","author":"M Scharr","year":"2024","unstructured":"Scharr M, Hirt B, Neckel PH (2024) Spatial gene expression profile of Wnt-signaling components in the murine enteric nervous system. Front Immunol 15:1302488. https:\/\/doi.org\/10.3389\/fimmu.2024.1302488","journal-title":"Front Immunol"},{"issue":"1","key":"4906_CR107","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12964-023-01456-y","volume":"22","author":"L Tan","year":"2024","unstructured":"Tan L, Yan M, Su Z, Wang H, Li H, Zhao X et al (2024) R-spondin-1 induces Axin degradation via the LRP6-CK1\u03b5 axis. Cell Communication Signal 22(1):14. https:\/\/doi.org\/10.1186\/s12964-023-01456-y","journal-title":"Cell Communication Signal"},{"issue":"1","key":"4906_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.22074\/cellj.2023.2010157.1396","volume":"26","author":"S Ghobakhloo","year":"2024","unstructured":"Ghobakhloo S, Khoshhali M, Vatandoost N, Jafarpour S, Niazmand A, Nedaeinia R et al (2024) Clinical Implications and Prognostic Value of Leucine-Rich G Protein-Coupled Receptor 5 Expression as A Cancer Stem Cell Marker in Malignancies: A Systematic Review and Meta-Analysis. Cell J 26(1):1\u201312. https:\/\/doi.org\/10.22074\/cellj.2023.2010157.1396","journal-title":"Cell J"},{"key":"4906_CR109","doi-asserted-by":"publisher","first-page":"1334631","DOI":"10.3389\/fonc.2024.1334631","volume":"14","author":"T Liu","year":"2024","unstructured":"Liu T, Li X, Li H, Qin J, Xu H, Wen J et al (2024) Intestinal organoid modeling: bridging the gap from experimental model to clinical translation. Front Oncol 14:1334631. https:\/\/doi.org\/10.3389\/fonc.2024.1334631","journal-title":"Front Oncol"},{"issue":"7","key":"4906_CR110","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.3390\/medicina59071233","volume":"59","author":"EM Ahmed","year":"2023","unstructured":"Ahmed EM, Farag AS, Abdelwahed MS, Hanbazazh M, Samman A, Ashmawy D et al (2023) The Expression of Stem Cell Marker LGR5 and Its Coexpression with Beta-Catenin in Sporadic Colorectal Carcinoma and Adenoma: A Comparative Immunohistochemical Study. Med (Kaunas) 59(7):1233. https:\/\/doi.org\/10.3390\/medicina59071233","journal-title":"Med (Kaunas)"},{"issue":"7","key":"4906_CR111","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1158\/1535-7163.MCT-16-0114","volume":"15","author":"X Gong","year":"2016","unstructured":"Gong X, Azhdarinia A, Ghosh SC, Xiong W, An Z, Liu Q et al (2016) LGR5-Targeted Antibody-Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence. Mol Cancer Ther 15(7):1580\u20131590. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0114","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"4906_CR112","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40164-024-00474-x","volume":"13","author":"Q Zhao","year":"2024","unstructured":"Zhao Q, Zong H, Zhu P, Su C, Tang W, Chen Z et al (2024) Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs. Experimental Hematol Oncol 13(1):6. https:\/\/doi.org\/10.1186\/s40164-024-00474-x","journal-title":"Experimental Hematol Oncol"},{"issue":"314","key":"4906_CR113","doi-asserted-by":"publisher","first-page":"314ra186","DOI":"10.1126\/scitranslmed.aac7433","volume":"7","author":"MR Junttila","year":"2015","unstructured":"Junttila MR, Mao W, Wang X, Wang BE, Pham T, Flygare J et al (2015) Targeting LGR5\u2009+\u2009cells with an antibody-drug conjugate for the treatment of colon cancer. Sci Transl Med 7(314):314ra186. https:\/\/doi.org\/10.1126\/scitranslmed.aac7433","journal-title":"Sci Transl Med"},{"issue":"7","key":"4906_CR114","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1158\/1535-7163.MCT-12-1173","volume":"12","author":"D Li","year":"2013","unstructured":"Li D, Poon KA, Yu S-F, Dere R, Go M, Lau J et al (2013) DCDT2980S, an anti-CD22-monomethyl auristatin E antibody\u2013drug conjugate, is a potential treatment for non-Hodgkin lymphoma. Mol Cancer Ther 12(7):1255\u20131265. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-1173","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"4906_CR115","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/nbt.1480","volume":"26","author":"JR Junutula","year":"2008","unstructured":"Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S et al (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26(8):925\u2013932. https:\/\/doi.org\/10.1038\/nbt.1480","journal-title":"Nat Biotechnol"},{"issue":"2","key":"4906_CR116","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.stem.2013.11.008","volume":"14","author":"C Metcalfe","year":"2014","unstructured":"Metcalfe C, Kljavin NM, Ybarra R, de Sauvage FJ (2014) Lgr5\u2009+\u2009stem cells are indispensable for radiation-induced intestinal regeneration. Cell Stem Cell 14(2):149\u2013159. https:\/\/doi.org\/10.1016\/j.stem.2013.11.008","journal-title":"Cell Stem Cell"},{"issue":"7368","key":"4906_CR117","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nature10408","volume":"478","author":"H Tian","year":"2011","unstructured":"Tian H, Biehs B, Warming S, Leong KG, Rangell L, Klein OD et al (2011) A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature 478(7368):255\u2013259. https:\/\/doi.org\/10.1038\/nature10408","journal-title":"Nature"},{"issue":"5","key":"4906_CR118","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s002800050995","volume":"44","author":"JC Mirsalis","year":"1999","unstructured":"Mirsalis JC, Schindler-Horvat J, Hill JR, Tomaszewski JE, Donohue SJ, Tyson CA (1999) Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance. Cancer Chemother Pharmacol 44(5):395\u2013402. https:\/\/doi.org\/10.1007\/s002800050995","journal-title":"Cancer Chemother Pharmacol"},{"issue":"24","key":"4906_CR119","doi-asserted-by":"publisher","first-page":"508","DOI":"10.21037\/atm.2016.11.78","volume":"4","author":"D Hirsch","year":"2016","unstructured":"Hirsch D, Ried T (2016) Targeting colorectal cancer (stem-like) cells using LGR5 directed antibody drug conjugates. Ann Transl Med 4(24):508. https:\/\/doi.org\/10.21037\/atm.2016.11.78","journal-title":"Ann Transl Med"},{"issue":"2","key":"4906_CR120","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1021\/acs.biomac.2c01269","volume":"24","author":"U Huynh","year":"2023","unstructured":"Huynh U, Wu P, Qiu J, Prachyathipsakul T, Singh K, Jerry DJ et al (2023) Targeted Drug Delivery Using a Plug-to-Direct Antibody-Nanogel Conjugate. Biomacromolecules 24(2):849\u2013857. https:\/\/doi.org\/10.1021\/acs.biomac.2c01269","journal-title":"Biomacromolecules"},{"issue":"15","key":"4906_CR121","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1039\/d3bm00664f","volume":"11","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Zhang H, Cui L, Wang X, Wang D, Liu Z et al (2023) An MMAE-loaded PDL1 active targeting nanomedicine for the precision treatment of colon cancer. Biomaterials Sci 11(15):5195\u20135204. https:\/\/doi.org\/10.1039\/d3bm00664f","journal-title":"Biomaterials Sci"},{"issue":"1","key":"4906_CR122","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00204-022-03396-x","volume":"97","author":"J Xue","year":"2023","unstructured":"Xue J, Lou X, Ning D, Shao R, Chen G (2023) Mechanism and treatment of \u03b1-amanitin poisoning. Arch Toxicol 97(1):121\u2013131. https:\/\/doi.org\/10.1007\/s00204-022-03396-x","journal-title":"Arch Toxicol"},{"issue":"2","key":"4906_CR123","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1158\/1535-7163.MCT-20-0287","volume":"20","author":"V Figueroa-Vazquez","year":"2021","unstructured":"Figueroa-Vazquez V, Ko J, Breunig C, Baumann A, Giesen N, Palfi A et al (2021) HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells. Mol Cancer Ther 20(2):367\u2013378. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0287","journal-title":"Mol Cancer Ther"},{"issue":"7Supplement","key":"4906_CR124","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1158\/1538-7445.Am2023-2636","volume":"83","author":"A Braun","year":"2023","unstructured":"Braun A, Pelz A, Ebeling F, Decker K, P\u00e1lfi A, Kulke M et al (2023) Abstract 2636: Amanitin-based ADCs targeting Guanylyl cyclase C (GCC) as novel therapeutic modality for treatment of colorectal cancer. Cancer Res 83(7Supplement):2636. https:\/\/doi.org\/10.1158\/1538-7445.Am2023-2636","journal-title":"Cancer Res"},{"key":"4906_CR125","doi-asserted-by":"publisher","first-page":"1320766","DOI":"10.3389\/fonc.2024.1320766","volume":"14","author":"B Vonniessen","year":"2024","unstructured":"Vonniessen B, Tabari\u00e8s S, Siegel PM (2024) Antibody-mediated targeting of Claudins in cancer. Front Oncol 14:1320766. https:\/\/doi.org\/10.3389\/fonc.2024.1320766","journal-title":"Front Oncol"},{"issue":"11","key":"4906_CR126","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1158\/0008-5472.CAN-17-1869","volume":"78","author":"S Paquet-Fifield","year":"2018","unstructured":"Paquet-Fifield S, Koh SL, Cheng L, Beyit LM, Shembrey C, M\u00f8lck C et al (2018) Tight junction protein claudin-2 promotes self-renewal of human colorectal cancer stem-like cells. Cancer Res 78(11):2925\u20132938. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1869","journal-title":"Cancer Res"},{"issue":"4","key":"4906_CR127","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1369\/0022155413479123","volume":"61","author":"A Holczbauer","year":"2013","unstructured":"Holczbauer A, Gyongyosi B, Lotz G, Szijarto A, Kupcsulik P, Schaff Z et al (2013) Distinct claudin expression profiles of hepatocellular carcinoma and metastatic colorectal and pancreatic carcinomas. J Histochem Cytochem 61(4):294\u2013305. https:\/\/doi.org\/10.1369\/0022155413479123","journal-title":"J Histochem Cytochem"},{"issue":"3","key":"4906_CR128","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3390\/biom14030272","volume":"14","author":"KE Cox","year":"2024","unstructured":"Cox KE, Liu S, Hoffman RM, Batra SK, Dhawan P, Bouvet M (2024) The Expression of the Claudin Family of Proteins in Colorectal Cancer. Biomolecules 14(3):272. https:\/\/doi.org\/10.3390\/biom14030272","journal-title":"Biomolecules"},{"issue":"1","key":"4906_CR129","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s42003-021-02189-9","volume":"4","author":"S Tabari\u00e8s","year":"2021","unstructured":"Tabari\u00e8s S, Annis MG, Lazaris A, Petrillo SK, Huxham J, Abdellatif A et al (2021) Claudin-2 promotes colorectal cancer liver metastasis and is a biomarker of the replacement type growth pattern. Commun Biology 4(1):657. https:\/\/doi.org\/10.1038\/s42003-021-02189-9","journal-title":"Commun Biology"},{"issue":"2","key":"4906_CR130","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/j.jss.2010.02.010","volume":"167","author":"H Jung","year":"2011","unstructured":"Jung H, Jun KH, Jung JH, Chin HM, Park WB (2011) The expression of claudin-1, claudin-2, claudin-3, and claudin-4 in gastric cancer tissue. J Surg Res 167(2):e185\u2013e191. https:\/\/doi.org\/10.1016\/j.jss.2010.02.010","journal-title":"J Surg Res"},{"key":"4906_CR131","doi-asserted-by":"publisher","unstructured":"Tabari\u00e8s S, Robert A, Marcil A, Ling B, Acchione M, Lippens J et al (2024) Anti-Claudin-2 Antibody\u2013Drug Conjugates for the Treatment of Colorectal Cancer Liver Metastasis. Mol Cancer Ther OF1\u2013OF12. https:\/\/doi.org\/10.1158\/1535-7163.MCT-23-0393","DOI":"10.1158\/1535-7163.MCT-23-0393"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04906-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04906-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04906-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T03:39:33Z","timestamp":1779939573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04906-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":131,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4906"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04906-9","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}